Stock info Acadia Pharmaceuticals | Filter  Basic-Info

Acadia Pharmaceuticals

The past year gave good returns for Acadia Pharmaceuticals investors

Over the period from December 2015 till December 2016 the stock lost around 13 percent. Over the period 2011-2016 the stock rose a massive 2215,08 percent. Acadia Pharmaceuticals's revenues between 2011 and 2015 were far from constant and moved between 4,91 million dollars and 0,06 million dollars. Acadia Pharmaceuticals's net incomes between 2011 and 2015 were very volatile and moved between -22,77 million dollars and -164,44 million dollars.

Acadia Pharmaceuticals has her headquarter located in San Diego. The company mostly operates in the pharmaceutical sector. Acadia Pharmaceuticals is being led by CEO Dr. Uli Hacksell Ph.D. Mr. Stephen R. Davis J.D runs the company as a CFO. The past 10 years the (international) industry gained at around 75 percent. Over the past 5 years the sector is 147 percent higher.

The American company didn't pay out any dividends (in the past 5 years).

Quite a lot of debt Acadia Pharmaceuticals

At the end of 2015 the American company had a balance sheet of 221,9 million dollars. The total debt was around 22,14 million dollars. This is 9,98 percent of the total balance sheet. As per the end of 2015 Acadia Pharmaceuticals's price/earnings-ratio equaled -19. So investors paid for 1 stock -19 times the earnings per share of 2015. Many analysts say that based on her price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the pharmaceutical company's market capitalization (the number of shares times the market price) equaled around 3,49 billion dollars. At the end of 2015 the American company had around 100,63 million stocks listed on the exchanges.

All Acadia Pharmaceuticals's financial reports are available here. More information about Acadia Pharmaceuticals can be found it's website. .